Project #113:
Shared care monitoring: the impact of COVID-19 and factors associated with resilience

This study aims to evaluate whether the COVID-19 pandemic affected the completion of shared care drug monitoring. It also considers whether any such effect was associated with other variables, such as patient demographics or comorbidities.

The analysis will cover all patients registered with a GP practice aged 18 years and over, who are currently prescribed currently prescribed Azathioprine, Methotrexate, Mercaptopurine, Mycophenolate, Leflunomide or Levothyroxine.

Understanding the impact of COVID-19 on monitoring is important, as in the short-term this will lay the foundation for an analysis of the health impact and recovery planning, and in the longer-term an analysis of whether current monitoring recommendations remain appropriate. Furthermore, understanding factors which underpin variance in resilience to the impact of COVID-19 on monitoring adherence may be valuable learning points, with a view to increasing the resilience of the population overall, and reducing health inequalities between the least and most resilient segments.